Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9627MR)

This product GTTS-WQ9627MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ9627MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12870MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA OPN-305
GTTS-WQ8866MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ10542MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY-3015014
GTTS-WQ72MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ12908MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ222MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 13C5.5
GTTS-WQ5997MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CNTO 095
GTTS-WQ10544MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY-3015014
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW